SANUWAVE, Inc. Enrolls First Diabetic Foot Ulcer Patient in the dermaPACE Clinical Trial

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ALPHARETTA, Ga., June 5, 2013 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that the first patient has been enrolled and begun treatment in the supplemental Phase III clinical trial of the Company’s dermaPACE® device for treating diabetic foot ulcers. The clinical trial is designed to enroll a minimum of 90 patients at up to 20 U.S. sites.

Help employers find you! Check out all the jobs and post your resume.